Acutaas Chemicals Limited — PPTs, 28-01-2026: Investor Presentation

Acutaas Chemicals reported strong Q3 FY26 results.

1. **Business Performance:** Revenue jumped 43% YoY to ₹393.2 Cr, driven by robust growth in Advanced Pharmaceutical Intermediates, especially from CDMO ramp-up. EBITDA soared 119.4% YoY to ₹150.7 Cr (38.3% margin), and Net Profit (PAT) surged 133.7% YoY to ₹106.2 Cr (27% margin), marking its highest ever quarterly PAT. For the first nine months of FY26, revenue stood at ₹906.6 Cr, up 29.8% YoY, with PAT at ₹222.1 Cr, a 127.3% increase.

2. **Growth Drivers or Strategy:** The company is reinforcing its core pharma intermediates business through new CMO/CDMO opportunities. It's also building out battery chemicals and semiconductor chemicals verticals, aiming for each to be a self-sustaining growth engine in three years.

3. **Recent Developments:** Q3 momentum was fueled by the CDMO business ramp-up, better cost management, and a favorable product mix.

4. **Key Financial Metrics:** (Included above in Business Performance for conciseness)

5. **Management Commentary / Outlook:** Management revised its FY26 revenue growth outlook upwards from 25% to approximately 30%, citing a healthy order book and improved visibility.